A101140 Stock Overview
INBIOGEN CO.Ltd manufactures and sells footwear for children, youth, and adults in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INBIOGEN Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩467.00 |
| 52 Week High | ₩2,650.00 |
| 52 Week Low | ₩462.00 |
| Beta | 1.21 |
| 11 Month Change | 0% |
| 3 Month Change | -2.30% |
| 1 Year Change | -71.95% |
| 33 Year Change | -86.73% |
| 5 Year Change | -80.70% |
| Change since IPO | -96.59% |
Recent News & Updates
Shareholder Returns
| A101140 | KR Luxury | KR Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | -0.7% |
| 1Y | -72.0% | -16.8% | -4.1% |
Return vs Industry: A101140 underperformed the KR Luxury industry which returned -13.3% over the past year.
Return vs Market: A101140 underperformed the KR Market which returned 8% over the past year.
Price Volatility
| A101140 volatility | |
|---|---|
| A101140 Average Weekly Movement | n/a |
| Luxury Industry Average Movement | 4.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A101140 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A101140's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | n/a | Moo-Hyung Choi | www.inbiogen.co.kr |
INBIOGEN CO Ltd manufactures and sells footwear for children, youth, and adults in South Korea and internationally. The company markets its products under the ARTIS, SPECS, WANGJA, NEOSPEC, and CHAMPION brands.
INBIOGEN Co., Ltd. Fundamentals Summary
| A101140 fundamental statistics | |
|---|---|
| Market cap | ₩65.30b |
| Earnings (TTM) | -₩57.30b |
| Revenue (TTM) | ₩10.58b |
6.2x
P/S Ratio-1.1x
P/E RatioIs A101140 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A101140 income statement (TTM) | |
|---|---|
| Revenue | ₩10.58b |
| Cost of Revenue | ₩8.10b |
| Gross Profit | ₩2.48b |
| Other Expenses | ₩59.78b |
| Earnings | -₩57.30b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -409.76 |
| Gross Margin | 23.45% |
| Net Profit Margin | -541.63% |
| Debt/Equity Ratio | 0.8% |
How did A101140 perform over the long term?
See historical performance and comparison